Mike Ulz's questions to Y-mAbs Therapeutics Inc (YMAB) leadership • Q3 2024
Question
Representing Mike Ulz, Rohit asked for a breakdown of the Q3 DANYELZA sales decline, attributing it to seasonality, competition, and clinical trials, and requested more detail on the change in estimate for Medicaid claims.
Answer
Chief Financial Officer Pete Pfreundschuh clarified that the number of sites with higher Medicaid populations is increasing, leading to a $1.5 million downward adjustment in Q3. He also noted a $700,000 shipment timing issue that pushed sales into Q4. Chief Commercial Officer Sue Smith added that despite headwinds, key performance indicators like physician and patient starts are growing, particularly in high-volume centers, driven by a new competitive campaign focused on DANYELZA's value proposition.